Projects on T cells and advanced therapy medicinal products for rare diseases, patient reported outcomes in cancer clinical trials, and improvements to patient drug information are among the latest topics to be offered funding under Europe’s Innovative Medicines Initiative.
Europe’s Innovative Medicines Initiative is offering €45m ($51m) in funding for new research projects to support the development of T-cell therapies for use in both hematological and solid tumors and to speed up the generation of knowledge about the use of advanced (gene and cell) therapies in the treatment of rare diseases.
The IMI, a joint enterprise between the European pharmaceutical industry body EFPIA and the EU’s Horizon 2020 R&D innovation program,...
<p>Executive Summary</p> <p>A list of EU biosimilar filings, CHMP opinions and EU marketing authorizations, including details of the biosimilar company, the brand name/INN, indication(s), the reference product/company, and the date and type of event.</p>
As the reform of the EU pharmaceutical legislation progresses through the legislative process, the Pinks Sheet offers an infographic highlighting some of the key changes being proposed that will reshape the way drug companies run their business.
<p>Executive Summary<p> <p>The Pink Sheet's list of EU centralized approvals of new active substances has been updated to add six new products, incl/ding Ixchiq, Valneva's chikungunya virus vaccine</p>
A new research ethics review system for multi-site clinical trials in Canada is expected to help improve study start-up times, avoid unnecessary duplication and boost the country’s competitiveness on a global stage.
With the deadline for comments on the US FDA’s draft guidance less than a month away, the Pink Sheet offers an infographic outlining what the agency is expecting in diversity action plans and when that might be implemented.
